Asia Pacific Over the Counter (OTC) Drugs Market Size & Share 2025 - 2034

Asia Pacific Over the Counter Drugs Market Size

The Asia Pacific over the counter drugs market was estimated at USD 50 billion in 2024. The market is expected to grow from USD 52.2 billion in 2025 to USD 90.5 billion in 2034, growing at a CAGR of 6.3% from 2025 to 2034, according to the latest report published by Global Market Insights Inc. The growing aging population in the region is a key factor driving the demand for OTC drugs, as the geriatric population is more susceptible to chronic illnesses such as joint pain, respiratory ailments, and digestive issues, among others.

For instance, Japan leads the world with over 29% of its population aged 65 and above. China, too, had more than 310 million people aged 60 and above in 2024, according to the State Council Information Office. This highlights a large population susceptible to chronic conditions requiring long-term treatment, thereby contributing to the adoption of OTC medications in the region.
 

Over the counter (OTC) drugs are medications that can be directly purchased from pharmacies without the need for a doctor’s prescription. These drugs are used for managing various conditions such as pain relief, allergy management, digestive health, dermatological issues, and dietary requirements. The Asia Pacific OTC drugs market is characterized by the presence of several global and domestic pharmaceutical players. Top 6 players such as Haleon, Kenvue, Bayer, Procter & Gamble Company, Sanofi, and Taisho Pharmaceuticals account for around 19 – 22% of market share. These players maintain a competitive edge owing to their strong visibility, brand recognition, robust distribution network, and diversified product portfolios. Further, these players are focusing on expanding their reach across the region through different marketing strategies, partnerships, and collaborations with retail pharmacies and increasing R&D expenditures to launch innovative formulations.
 

The Asia Pacific OTC drugs market witnessed stable growth from USD 45.9 billion in 2021 to USD 48.2 billion in 2023. A key trend during this period was the growing awareness of preventive healthcare, immunity building, and increased adoption of self-medication. This has drastically driven the demand for vitamins, pain relief medicines, cold and cough remedies, and digestive care medications, eliminating the need for hospital or clinic visits.
 

OTC drugs are non-prescription medications that can be purchased directly without a physician's prescription. These drugs are regulated by health authorities to ensure safety and efficacy. They are available as tablets, ointments, solutions, sprays, and other dosage forms that can be conveniently self-administered by patients, thus eliminating the need for a doctor’s prescription.
 

Asia Pacific Over the Counter Drugs Market Trends

• A key trend shaping the growth of the Asia Pacific OTC drugs industry is the increasing number of OTC drug approvals combined with the growing regulatory shift supporting these approvals.
   
• For instance, as per the China National Medical Products Administration (NMPA), as of September 2022, 5,041 OTC drugs, including 1,111 chemical drugs, 3,921 traditional Chinese medicines, and 9 biological products, were approved. This increasing number of OTC drug approvals accelerates their adoption, thereby boosting market growth.
   
• Another trend driving the growth of this market is the increasing reclassification of prescription drugs into OTC drug categories. For example, among the OTC drugs approved in 2022 by the China National Medical Products Administration (NMPA), 805 were earlier prescription drugs and were granted OTC status via Rx-to-OTC switch; additionally, among these 805 drugs, 192 have both prescription and OTC statuses.
   
• This shift from prescription to over-the-counter status is broadening consumer access, reducing financial burdens, and minimizing the pressure on healthcare systems by significantly expanding the range of medications available over the counter.
   
• Moreover, it also encourages pharmaceutical companies to invest in R&D to develop new delivery formulations such as gummies, softgels, and dissolvable strips, among others. These innovations foster the adoption of OTC drugs due to increased patient comfort and adherence to the treatment.
   
• Further, a well-established network of retail pharmacy chains such as Apollo Pharmacy, Watsons, and Guardian in countries like India, Singapore, and Hong Kong has improved access to OTC products.
   
• Moreover, beyond disease management, OTC drugs are increasingly adopted for wellness, energy, skin health, and fitness trends. Vitamins and supplements involved in boosting energy levels, dermatological care, and weight management are gaining traction among young and urban consumers. This growing shift towards holistic wellness and lifestyle further enhances the growth of the OTC drugs market in the region.
   

Asia Pacific Over the Counter Drugs Market Analysis

Based on the drug category, the Asia Pacific over the counter drugs market is segmented into cold and cough remedies, vitamins and supplements, digestive and intestinal remedies, skin treatment, analgesics, sleeping aids, and other drug categories. The cold and cough remedies segment dominated the market and was valued at USD 12.1 billion in 2024, driven by the rising incidence rate of respiratory infections, such as cold, cough, flu, and other viral infections caused by pollutants or seasonal outbreaks.
 

• As per the Journal of The Association of Physicians of India, cough is the second common symptom seen by general practitioners, and its prevalence ranges from 5–10% in India. This growing concern ensures that the cold and cough remedies remain a necessity, thereby reinforcing their dominant share in the market.
   

• Additionally, the availability of OTC cold and cough remedies in a wide array of formulations such as syrups, lozenges, sprays, and tablets makes them suitable for various age groups. This versatility, therefore, drives regular purchases and adoption across diverse populations.
   
• The vitamins and supplements segment, on the other hand, is expected to witness high growth at a CAGR of 6.9% during the forecast period.
   
• Rapid urbanization and changing dietary habits have led to nutritional deficiencies, prompting consumers to supplement their nutrition. Thus, the widespread availability of OTC vitamins and supplements fulfils the growing demand of consumers and positions it as the fastest-growing segment in the Asia Pacific OTC drugs market.

Learn more about the key segments shaping this market

Download Free PDF

Based on the formulation type, the Asia Pacific OTC drugs market is classified into tablets, liquids, ointments, and sprays. In 2024, the tablets segment dominated the market with 63.6% of market share and is anticipated to grow at a 6.6% CAGR over the analysis period.
 

• The growth of the tablets segment is primarily due to its widespread consumer acceptance and convenience of use. Tablets are the most preferred formulation type across all age groups as they are easy to store and consume.
   
• Additionally, their longer shelf life compared to liquid and other formulations further reinforces their dominant position.
   
• Moreover, the availability of a wide range of OTC drugs such as pain relievers, antihistamines, vitamins, and supplements, as well as digestive health products in tablet form, further drives the growth of this segment.
   
• On the other hand, the liquids segment is anticipated to witness growth at a 6.1% CAGR during the forecast period, driven by their growing adoption among children and the elderly population with swallowing issues.
   
• Additionally, the growth of this segment can be attributed to the fast onset of action that liquids provide, as the active ingredients are already dissolved, leading to quick absorption in the body.
   

Based on the distribution channel, the Asia Pacific OTC drugs market is segmented into online channels and offline channels. The offline channels segment dominated the market in 2024 and is expected to reach USD 64.2 billion by 2034. The offline channels segment is sub-segmented into hospital pharmacies, retail pharmacies, and other offline channels. On the other hand, the online channels segment accounted for USD 13.6 billion in 2024, driven by the growing penetration of e-commerce in key markets such as China, India, Indonesia, and South Korea. Additionally, the COVID-19 pandemic has significantly accelerated the shift towards online purchase of healthcare products, including OTC drugs.
 

• The hospital pharmacies and retail pharmacies are the primary point of purchase for OTC drugs in Asia Pacific countries due to the trust consumers place in these channels.
   
• In countries such as China, India, and Japan, pharmacists often provide consultation for minor ailments such as cough, cold, fever, and digestive issues. Thus, this health advice from pharmacists further reinforces consumer reliance on offline channels.
   
• Additionally, the availability of various formulations and novel drugs further increases the accessibility of OTC drugs in offline channels.
   

China Over the Counter Drugs Market
 

China market was valued at USD 15.1 billion and USD 15.4 billion in 2021 and 2022, respectively. The market size reached USD 16.6 billion in 2024, growing from USD 16 billion in 2023.
 

• According to the World Health Organization, China has one of the fastest-growing ageing populations in the world. In 2019, there were 254 million people aged 60 and over, and it is expected to reach 402 million by 2040.
   
• This rapidly aging population represents high demand for accessible and affordable treatment options.
   
• Another factor driving the growth of China's OTC drugs market is the strong culture of self-medication in the country. Consumers are emphasizing preventive healthcare and prefer OTC remedies to manage mild symptoms instead of visiting hospitals and clinics.
   

India OTC Drugs Market
 

India market is anticipated to grow at a significant CAGR over the analysis period.
 

• In India, the growing adoption of digital health and e-pharmacy is driving the growth of the OTC drugs market.
   
• For instance, as per an article published by O.P. Jindal Global University, during the pandemic, 8.8 million of the roughly 300 million households procured medicines through e-pharmacies, compared to 3.5 million in the pre-COVID-19 phase.
   
• This growing adoption of e-pharmacies supports the growth of OTC drugs.
   
• Furthermore, the availability of OTC drugs on platforms such as Reliance, Amazon, Practo, Flipkart, Apollo, PharmEasy, and Tata Group in India contributes to easy accessibility in urban as well as rural areas in the country, thereby fostering market growth.
   

Japan Over the Counter Drugs Market
 

Japan OTC drugs market is expanding rapidly in the overall Asia Pacific OTC drugs market with 6.4% CAGR during the forecast period.
 

• The market in Japan is characterized by innovation and product diversification. The presence of robust pharmaceutical companies such as Taisho Pharmaceuticals and Alinamin Pharmaceutical is supporting the growth of this market.
   
• Moreover, the widespread distribution networks in Japan facilitate easy access to OTC drugs for a wide range of health conditions, including pain relief, digestive health, and vitamins, thereby driving the growth of this market.
   

Indonesia is emerging as a high-growth market for OTC drugs within the Asia Pacific region, driven by a mix of demographic and economic factors.
 

• A large population, coupled with rising disposable incomes, has encouraged greater reliance on self-care and easy access to medicines.
   
• The government’s expanding national health insurance scheme has also improved awareness of basic treatments, boosting demand for affordable OTC products in the country.
   

Asia Pacific Over the Counter Drugs Market Share

The Asia Pacific OTC drugs industry is characterized by intense competition, with participation from multinational global companies, regional players, and emerging brands. Top 6 players such as Haleon, Kenvue, Bayer, Procter & Gamble Company, Sanofi, and Taisho Pharmaceuticals account for ~20.7% of market share. These players focus on various strategies such as business expansion, mergers and acquisitions, collaborations, and novel product launches to consolidate their market presence.
 

Many companies are also increasing investments in research and development to create safer, more effective OTC products with fewer side effects. Efforts to expand access in underserved regions and improve affordability further underscore the market’s shift toward global inclusivity, preventive care, and personalized wellness.
 

Asia Pacific Over the Counter Drugs Market Companies

Few of the prominent players operating in the Asia Pacific OTC drugs industry include:

• Abbott Laboratories
• Alinamin Pharmaceutical
• Alkem Laboratories
• Bayer
• Cipla
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Haleon
• Himalaya Wellness Company
• Kenvue
• Perrigo Company
• Piramal Pharma
• Procter & Gamble Company
• Reckitt
• Sanofi
• STADA Arzneimittel
• Sun Pharma
• Taisho Pharmaceutical
• Teva Pharmaceutical
   
• Haleon

Haleon holds a leading position in the Asia Pacific OTC drugs market with a share of 5.3%, leveraging its strong portfolio of trusted brands across pain relief, respiratory health, digestive care, and vitamins and minerals. In 2024, the company reinforced its leadership by expanding its presence in high-growth regions such as Asia-Pacific and Latin America, while maintaining strong positions in North America and Europe.
 

• Kenvue

Kenvue holds a growing position in the Asia Pacific OTC drugs market, driven by its portfolio of iconic brands such as Tylenol, Motrin, and Zyrtec. The company also introduced next-generation OTC formulations, such as Tylenol+ with added immune support, and expanded its product line to include natural alternatives.
 

• Bayer

Bayer is one of the leading players in the Asia Pacific OTC drugs market, driven by trusted brands and a commitment to advancing self-care. With a portfolio that includes widely recognized names such as Aspirin, Claritin, and Canesten, Bayer has positioned itself as a leader in key therapeutic areas, such as pain relief, allergy management, dermatology, digestive health, and cardiovascular support.
 

Asia Pacific Over the Counter Drugs Industry News:

• In June 2024, Dr. Reddy’s Laboratories announced an agreement to acquire Haleon’s global Nicotine Replacement Therapy (NRT) portfolio outside the U.S., including brands such as Nicotinell, Nicabate, Thrive, and Habitrol. The acquisition covers lozenge, patch, gum formats, and pipeline products across over 30 countries.
   
• In May 2024, Piramal Pharma expressed openness to forming partnerships within India’s OTC segment as part of its broader strategy focused on organic growth and reducing debt. This approach allows the company to expand its consumer healthcare footprint while maintaining financial discipline and leveraging collaborative growth opportunities.
   
• In April 2024, Glenmark Pharmaceuticals received FDA approval for its Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), deemed bioequivalent to Advil Dual Action with Acetaminophen. This helped the company expand its OTC product offerings.
   

The Asia Pacific over the counter drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Category

• Cold and cough remedies
• Vitamins and supplements
• Digestive and intestinal remedies
• Skin treatment
• Analgesics
• Sleeping aids
• Other drug categories

Market, By Formulation Type

• Tablets
• Liquids
• Ointments
• Sprays

Market, By Distribution Channel

• Online channels
• Offline channels
  • Hospital pharmacies
  • Retail pharmacies
  • Other offline channels

The above information is provided for the following countries:

• China
• Japan
• India
• Australia
• South Korea
• Indonesia
• Vietnam
• Malaysia
• Thailand
• Rest of Asia Pacific